Q1 2020 Earnings Estimate for Charles River Laboratories Intl. Inc (NYSE:CRL) Issued By William Blair

Share on StockTwits

Charles River Laboratories Intl. Inc (NYSE:CRL) – Research analysts at William Blair dropped their Q1 2020 earnings per share (EPS) estimates for shares of Charles River Laboratories Intl. in a report issued on Tuesday, February 11th. William Blair analyst J. Kreger now expects that the medical research company will earn $1.58 per share for the quarter, down from their previous forecast of $1.67. William Blair also issued estimates for Charles River Laboratories Intl.’s Q2 2020 earnings at $1.92 EPS, Q3 2020 earnings at $1.95 EPS, Q4 2020 earnings at $2.13 EPS and FY2020 earnings at $7.57 EPS.

A number of other research analysts have also recently commented on CRL. Robert W. Baird reiterated an “outperform” rating and issued a $185.00 price target (up from $165.00) on shares of Charles River Laboratories Intl. in a research note on Wednesday. Bank of America cut Charles River Laboratories Intl. from a “buy” rating to a “neutral” rating and set a $150.00 price target for the company. in a research note on Friday, October 18th. Barclays reiterated a “hold” rating and issued a $170.00 price target on shares of Charles River Laboratories Intl. in a research note on Wednesday. Cfra increased their price target on Charles River Laboratories Intl. from $165.00 to $180.00 and gave the company a “strong-buy” rating in a research note on Tuesday. Finally, KeyCorp increased their price target on Charles River Laboratories Intl. from $151.00 to $162.00 and gave the company an “overweight” rating in a research note on Monday, December 9th. Seven equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $169.33.

Shares of CRL opened at $176.48 on Thursday. Charles River Laboratories Intl. has a 52 week low of $123.17 and a 52 week high of $176.89. The stock has a market capitalization of $7.70 billion, a price-to-earnings ratio of 37.87, a PEG ratio of 1.77 and a beta of 1.18. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.20 and a current ratio of 1.43. The stock has a fifty day moving average of $157.46 and a 200-day moving average of $141.17.

Charles River Laboratories Intl. (NYSE:CRL) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $2.01 EPS for the quarter, beating the Zacks’ consensus estimate of $1.83 by $0.18. Charles River Laboratories Intl. had a return on equity of 21.52% and a net margin of 9.14%. The company had revenue of $691.10 million during the quarter, compared to analysts’ expectations of $685.46 million. During the same period in the prior year, the company earned $1.49 EPS. Charles River Laboratories Intl.’s revenue was up 14.1% compared to the same quarter last year.

Institutional investors have recently modified their holdings of the business. BlackRock Inc. grew its holdings in Charles River Laboratories Intl. by 1.6% in the 2nd quarter. BlackRock Inc. now owns 4,660,628 shares of the medical research company’s stock valued at $661,344,000 after buying an additional 72,827 shares during the last quarter. Envestnet Asset Management Inc. grew its holdings in Charles River Laboratories Intl. by 1.7% in the 3rd quarter. Envestnet Asset Management Inc. now owns 70,739 shares of the medical research company’s stock valued at $9,364,000 after buying an additional 1,196 shares during the last quarter. Oakbrook Investments LLC lifted its position in shares of Charles River Laboratories Intl. by 27.3% in the 3rd quarter. Oakbrook Investments LLC now owns 6,055 shares of the medical research company’s stock worth $802,000 after acquiring an additional 1,300 shares during the period. Park Avenue Securities LLC bought a new stake in shares of Charles River Laboratories Intl. in the 3rd quarter worth approximately $616,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Charles River Laboratories Intl. by 6.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,333 shares of the medical research company’s stock worth $441,000 after acquiring an additional 205 shares during the period. Hedge funds and other institutional investors own 95.78% of the company’s stock.

In other Charles River Laboratories Intl. news, VP Birgit Girshick sold 1,051 shares of the stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $145.55, for a total transaction of $152,973.05. Following the completion of the sale, the vice president now directly owns 18,728 shares in the company, valued at approximately $2,725,860.40. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Robert J. Bertolini sold 7,170 shares of the stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $170.41, for a total value of $1,221,839.70. Following the sale, the director now owns 31,905 shares of the company’s stock, valued at $5,436,931.05. The disclosure for this sale can be found here. Insiders sold 19,622 shares of company stock valued at $3,328,849 over the last 90 days. 1.80% of the stock is currently owned by company insiders.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Article: Quantitative Easing

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.